Comparison of Denosumab and Bisphosphonates in Patients With Osteoporosis: A Meta-Analysis of Randomized Controlled Trials

Lyu, Houchen, Jundi, Bakr, Xu, Chang, Tedeschi, Sara K, Yoshida, Kazuki, Zhao, Sizheng ORCID: 0000-0002-3558-7353, Nigwekar, Sagar U, Leder, Benjamin Z and Solomon, Daniel H (2019) Comparison of Denosumab and Bisphosphonates in Patients With Osteoporosis: A Meta-Analysis of Randomized Controlled Trials. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 104 (5). pp. 1753-1765.

Text Houchen JCEM.pdf - Author Accepted Manuscript Download (6MB)

Abstract

<h4>Context</h4>It is uncertain which osteoporosis therapy is more effective: bisphosphonates or denosumab.<h4>Objective</h4>To determine whether denosumab therapy increases bone mineral density (BMD) and reduces fracture risk more so than bisphosphonates in patients with low BMD or osteoporosis.<h4>Methods</h4>The PubMed, Embase, and the Cochrane Library databases were searched through November 2018 for head-to-head, randomized, controlled trials comparing denosumab and bisphosphonates among adult patients with low BMD or osteoporosis. Random-effects models were used.<h4>Results</h4>We identified 10 eligible trials including 5361 participants. Denosumab increased BMD more than bisphosphonate at 12 months (mean difference, 1.42%; 95% CI, 0.95% to 1.89%; P < 0.001) at lumbar spine, 1.11% (95% CI, 0.91% to 1.30%; P < 0.001) at total hip, and 1.00% (95% CI, 0.78% to 1.22%; P < 0.001) at femoral neck. At 24 months, the respective increase differences were 1.74% (95% CI, 1.05% to 2.43%; P < 0.001), 1.22% (95% CI, 0.66% to 1.77%; P < 0.001), and 1.19% (95% CI, 0.65% to 1.72%; P < 0.001). There was no difference in fracture end point at 12 months, but denosumab had a lower osteoporotic fracture incidence than alendronate at 24 months (risk ratio, 0.51; 95% CI, 0.27 to 0.97).<h4>Conclusion</h4>Denosumab improved BMD significantly more than bisphosphonate treatment at the lumbar spine, total hip, and femoral neck at 12 and 24 months. Only one study demonstrated greater osteoporotic fracture reduction with denosumab treatment. Longitudinal studies with longer follow-up and large sample size are needed to confirm the efficacy difference.

Item Type:	Article
Uncontrolled Keywords:	Humans, Osteoporosis, Diphosphonates, Prognosis, Bone Density Conservation Agents, Randomized Controlled Trials as Topic, Denosumab
Depositing User:	Symplectic Admin
Date Deposited:	21 Dec 2018 08:59
Last Modified:	19 Jan 2023 01:08
DOI:	10.1210/jc.2018-02236
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3030263